Veradermics, Inc (MANE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$168.4M
Cash & Equivalents
$21.2M
Quarterly Burn Rate
24 mo
Est. Cash Runway
$4,997M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase2 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2027-06-01 | Phase3 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07146022 | Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | PHASE3 | Recruiting | 552 |
| NCT06724614 | Efficacy and Safety of VDPHL01 in Males With AGA | PHASE3 | Active Not Recruiting | 480 |
| NCT06972264 | Safety and Efficacy of VDPHL01 in Males With AGA | PHASE3 | Active Not Recruiting | 480 |
| NCT06527365 | Safety and Efficacy of VDPHL01 in Males and Females With AGA | PHASE2 | Active Not Recruiting | 70 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.